Published in Lung Cancer on April 01, 1999
Machine learning and radiology. Med Image Anal (2012) 1.72
Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys (2010) 1.72
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer (2011) 1.66
Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys (2007) 1.42
LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol (2015) 1.38
Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol (2013) 1.20
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys (2011) 1.11
Emerging developments of chemoradiotherapy in stage III NSCLC. Nat Rev Clin Oncol (2012) 1.04
Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol (2012) 1.02
Functional image-based radiotherapy planning for non-small cell lung cancer: A simulation study. Radiother Oncol (2009) 0.96
Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol (2014) 0.92
On the use of hyperpolarized helium MRI for conformal avoidance lung radiotherapy. Med Dosim (2009) 0.89
Breathing-synchronized delivery: a potential four-dimensional tomotherapy treatment technique. Int J Radiat Oncol Biol Phys (2007) 0.88
Assessing the shift of radiobiological metrics in lung radiotherapy plans using 2D gamma index. Transl Lung Cancer Res (2016) 0.88
Endovascular coils as lung tumour markers in real-time tumour tracking stereotactic radiotherapy: preliminary results. Eur Radiol (2008) 0.87
Radiation dose effect in locally advanced non-small cell lung cancer. J Thorac Dis (2014) 0.87
(Radio)biological optimization of external-beam radiotherapy. Comput Math Methods Med (2012) 0.87
Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy. Sci Rep (2015) 0.85
Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer. Radiat Oncol (2007) 0.85
Intensity modulated radiotherapy: advantages, limitations and future developments. Biomed Imaging Interv J (2006) 0.84
Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond. Front Oncol (2014) 0.80
Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. Clin Lung Cancer (2015) 0.80
Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans. Radiat Oncol (2016) 0.79
An initial study on the estimation of time-varying volumetric treatment images and 3D tumor localization from single MV cine EPID images. Med Phys (2014) 0.79
Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer. Front Oncol (2013) 0.79
Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. Oncologist (2010) 0.79
Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2017) 0.79
Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability. Med Phys (2013) 0.78
Contouring variations and the role of atlas in non-small cell lung cancer radiation therapy: Analysis of a multi-institutional preclinical trial planning study. Pract Radiat Oncol (2014) 0.77
Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what? Transl Lung Cancer Res (2015) 0.77
Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis. Radiat Oncol (2015) 0.77
Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 0.77
Optimizing principal component models for representing interfraction variation in lung cancer radiotherapy. Med Phys (2010) 0.77
Dose-mass inverse optimization for minimally moving thoracic lesions. Phys Med Biol (2015) 0.77
Datamining approaches for modeling tumor control probability. Acta Oncol (2010) 0.76
Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation. Balkan Med J (2014) 0.76
Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep (2011) 0.76
SBRT in operable early stage lung cancer patients. Transl Lung Cancer Res (2014) 0.75
Stereotactic body radiotherapy in lung cancer: an update. J Bras Pneumol (2015) 0.75
Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. BMJ Open (2016) 0.75
Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer. Oncotarget (2016) 0.75
Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data? Radiat Oncol (2016) 0.75
Determination of acquisition frequency for intrafractional motion of pancreas in CyberKnife radiotherapy. ScientificWorldJournal (2014) 0.75
Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. J Thorac Dis (2014) 0.75
Pre-Chemoradiotherapy FDG PET/CT cannot Identify Residual Metabolically-Active Volumes within Individual Esophageal Tumors. J Nucl Med Radiat Ther (2015) 0.75
Evaluating the Toxicity Reduction With Computed Tomographic Ventilation Functional Avoidance Radiation Therapy. Int J Radiat Oncol Biol Phys (2017) 0.75
Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. Front Oncol (2017) 0.75
The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices. Transl Lung Cancer Res (2017) 0.75
Magnitude, Impact, and Management of Respiration-induced Target Motion in Radiotherapy Treatment: A Comprehensive Review. J Med Phys (2017) 0.75
Evaluating Which Dose-Function Metrics Are Most Critical for Functional-Guided Radiation Therapy. Int J Radiat Oncol Biol Phys (2017) 0.75
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys (1999) 4.24
Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer (2000) 4.05
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys (1998) 2.97
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst (1995) 2.64
A method for incorporating organ motion due to breathing into 3D dose calculations. Med Phys (1999) 2.28
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ (2010) 2.25
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2001) 2.18
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol (2000) 2.14
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res (2000) 2.14
Transmission of hormonal stimulation by cell-to-cell communication. Nature (1978) 2.08
Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys (1993) 2.07
Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys (1994) 2.00
Recent advances in radiation oncology. N Engl J Med (1995) 1.93
Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys (1999) 1.90
Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat (1983) 1.80
Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys (1998) 1.76
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74
Uncertainties in CT-based radiation therapy treatment planning associated with patient breathing. Int J Radiat Oncol Biol Phys (1996) 1.74
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 1.69
The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys (1992) 1.66
Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis (1999) 1.60
The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.56
Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys (1995) 1.54
Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.53
Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys (1996) 1.51
Defining the role of post-mastectomy radiotherapy: the new evidence. Oncology (Williston Park) (1996) 1.47
Breast microcalcifications after lumpectomy and radiation therapy. Radiology (1989) 1.46
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res (1999) 1.45
Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. Int J Radiat Oncol Biol Phys (1998) 1.44
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res (2001) 1.39
Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol (2000) 1.39
Improvement of CT-based treatment-planning models of abdominal targets using static exhale imaging. Int J Radiat Oncol Biol Phys (1998) 1.39
Maximum tolerated dose for low-dose continuous infusion cisplatin. Int J Radiat Oncol Biol Phys (1991) 1.39
Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res (1995) 1.39
Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol (2001) 1.37
Gap junctional communication. Annu Rev Physiol (1981) 1.35
Partial irradiation of the liver. Semin Radiat Oncol (2001) 1.35
The impact of treatment complexity and computer-control delivery technology on treatment delivery errors. Int J Radiat Oncol Biol Phys (1998) 1.32
Polymyositis: remarkable response to total body irradiation. Lancet (1981) 1.30
Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med (1987) 1.30
Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys (1984) 1.27
Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol (2001) 1.27
Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci U S A (1999) 1.26
Desmoid tumors--treatment and prognosis. Radiology (1977) 1.26
Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res (1994) 1.25
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene (2006) 1.25
Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood (1999) 1.24
Is uniform target dose possible in IMRT plans in the head and neck? Int J Radiat Oncol Biol Phys (2002) 1.24
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Hormonally induced cell shape changes in cultured rat ovarian granulosa cells. J Cell Biol (1979) 1.21
Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol (1988) 1.20
Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol (1993) 1.17
A stochastic approach to estimate the uncertainty involved in B-spline image registration. IEEE Trans Med Imaging (2009) 1.16
Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol (1997) 1.16
Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys (1995) 1.15
The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther (2002) 1.12
Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity. Proc Natl Acad Sci U S A (1992) 1.12
Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life. Acta Otorhinolaryngol Belg (1999) 1.11
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol (2001) 1.11
Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) (1982) 1.09
Inclusion of organ deformation in dose calculations. Med Phys (2003) 1.09
Automated localization of the prostate at the time of treatment using implanted radiopaque markers: technical feasibility. Int J Radiat Oncol Biol Phys (1995) 1.08
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol (1999) 1.07
Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol (1986) 1.07
Inverse plan optimization accounting for random geometric uncertainties with a multiple instance geometry approximation (MIGA). Med Phys (2006) 1.06
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol (2000) 1.06
Potential selection bias in a community-based study of PSA levels in African-American men. J Clin Epidemiol (2001) 1.06
Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys (1991) 1.06
A feasibility study of mutual information based setup error estimation for radiotherapy. Med Phys (2001) 1.05
Peripheral dose to the testes: the design and clinical use of a practical and effective gonadal shield. Int J Radiat Oncol Biol Phys (1985) 1.04